Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protocadherin 19 (PCDH19)
- Target
- PCDH19
- Molecular classification
- Non-clustered protocadherin, δ2-protocadherin subfamily, Cell adhesion protein, Other (member of cadherin superfamily)
01
Overview
Protocadherin 19 (PCDH19) is a member of the protocadherin family, specifically the δ2 subfamily of non-clustered protocadherins within the cadherin superfamily. It encodes a membrane protein with six extracellular cadherin repeats, a transmembrane domain, and a cytoplasmic tail, expressed mainly in the developing brain. PCDH19 mediates calcium-dependent homophilic cell–cell adhesion among neurons, contributing to the assembly of neural circuits and regulation of cell migration and positioning, as well as modulating actin/microtubule dynamics and GABAergic synaptic function. Germline mutations in PCDH19 cause a distinctive X-linked epilepsy syndrome (PCDH19-Clustering Epilepsy, formerly called "female-limited epilepsy") characterized by early-onset seizures and cognitive/psychiatric comorbidities, typically manifesting in females due to mosaic cell populations (male mosaicism is rare). PCDH19 interacts with several cytoskeletal and signaling proteins, notably β-catenin (affecting gene regulation) and GABA A receptor alpha subunits (regulating inhibitory neurotransmission). No drugs currently target PCDH19, but understanding its molecular interactions may enable future therapeutic development.
- Other names
- PCDH19Protocadherin-19CECR7
02
Mechanism of action
Null (no currently approved drugs targeting PCDH19)
03
Biological functions
Cell adhesionRegulation of cell signaling (notably β-catenin signaling)Neuronal developmentRegulation of GABAergic transmissionCytoskeletal organizationOther (modulation of neural network assembly)
04
Disease associations
Epilepsy (specifically PCDH19-Clustering Epilepsy)Neurodevelopmental disorders (e.g., intellectual disability, autism spectrum)Psychiatric disorders (emerging evidence)Other (potential involvement in cancer and developmental pathologies under investigation)
05
Safety considerations
Potential for broad neurological side effects due to the fundamental developmental and network role of PCDH19X-linked pattern with female-specific pathogenesis, raising challenges in therapy design and clinical trials
06
Interacting drugs
None established; no approved drugs directly target PCDH19 to date
07
Biomarkers
PCDH19 gene mutation (as a biomarker for PCDH19-Clustering Epilepsy diagnosis and genetic testing)Null (no established biomarker for therapy selection/monitoring)
Beyond the preview
Go deeper on Protocadherin 19 (PCDH19).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Protocadherin 19 (PCDH19).